Boston, MA 05/28/2013 (wallstreetpr) – In Friday’s trading session, ZIOPHARM Oncology Inc (NASDAQ:ZIOP) rose by 29.75%. It opened at $2.10 per share, touched an intraday high of $2.96 and dropped down to close at $2.08 per share. More than 16.77 million shares were traded in Friday’s trading session. This number stood above the average volume of 1.46 million that was measured over a 30-day period.
Very recently, ZIOPHARM Oncology Inc (NASDAQ:ZIOP) announced that Jonathan Lewis, CEO, is scheduled to present at the 38th Annual Deutsche Bank Health Care Conference that is to be held on 29 May 2013. This increased activity has boosted ZIOPHARM Oncology Inc (NASDAQ:ZIOP) into overbought territory. The company stock now has a 72.54 RSI. At current market valuation ZIOP has risen 33.91% on the SMA20 and 0.94 on the SMA50. The company’s technical chart shows that there has been a slight uptrend from the comparatively flat trading which prevailed since the beginning of May 2013. On an average, analysts have set a 2.88 target price for the stock.
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) is a bio-pharma company. It is focused on discovering and developing new cancer therapies. It is applying its technologies for cancer research to develop various therapeutics for patients. ZOIP’s portfolio is made up of five different clinical-stage product candidates and multiple research-stage candidates. ZIOPHARM Oncology Inc (NASDAQ:ZIOP)’s clinical programs include IL-12 DNA, palifosfamide (ZIO-201), darinaparsin (ZIO-101) and indibulin (ZIO-301). Palifosfamide is a deoxyribonucleic acid -targeted cancer treatment. It bypasses drug-resistance that has been mediated by aldehyde dehydrogenase.
